Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 5.50 · gapped above the open, then crossed back over prior close. High/low 5.54 at 2:00 pm ET, 5.43 at 10:45 am ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In November 2024, we entered into an exclusive license agreement (the "Biosion Agreement") with Biosion, Inc. ("Biosion") pursuant to which we received the exclusive rights to develop, manufacture and commercialize bosakitug (ATI-045) and ATI-052 worldwide, excluding Mainland China, Macau, Hong Kong and Taiwan ("Greater China").”
FILING10-K0001104659-26-020540cik 0001557746
“In August 2022, we entered into a non-exclusive patent license agreement with Lilly.”
FILING10-K0001104659-26-020540cik 0001557746
“In November 2022, we entered into a license agreement with Pediatrix Therapeutics, Inc. ("Pediatrix") under which we granted Pediatrix the exclusive rights to develop, manufacture and commercialize lepzacitinib in Greater China.”
FILING10-K0001104659-26-020540cik 0001557746
“In December 2023, we entered into an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc. ("Sun Pharma").”
FILING10-K0001104659-26-020540cik 0001557746
“In October 2019, we sold RHOFADE (oxymetazoline hydrochloride) cream, 1% ("RHOFADE"), to EPI Health, LLC ("EPI Health") pursuant to an asset purchase agreement.”
FILING10-K0001104659-26-020540cik 0001557746
“In July 2024, we entered into a royalty purchase agreement with OCM IP Healthcare Portfolio LP, an investment vehicle for Ontario Municipal Employees Retirement System ("OMERS").”
FILING10-K0001104659-26-020540cik 0001557746
Watchlist prices, news filtered to it, and its next report on your desk.
Aclaris Therapeutics, Inc. has 1 disclosed supplier and 5 disclosed customers. Each one is named in an SEC filing, either Aclaris Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Aclaris Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
ACRS (Aclaris Therapeutics, Inc.) has 1 disclosed suppliers and 5 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: LLY +0.05%, in healthcare.